Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Blood Pressure Medication Recalls

Recalls of ARBs, ACE inhibitors, beta blockers and other hypertension drugs - the class behind the large valsartan and losartan nitrosamine recalls.

549 recalls in this category, newest first.

Class II · Moderate risk

LOSARTAN POTASSIUM and HYDROCHLOROTHIAZIDE TABLETS

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-0505-2019
Class II · Moderate risk

LOSARTAN POTASSIUM and HYDROCHLOROTHIAZIDE TABLETS

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-0504-2019
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-0503-2019
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-0502-2019
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-0501-2019
Class II · Moderate risk

Valsartan and Hydrochlorothiazide Tablets

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Ongoing Nitrosamine impurity Mylan Laboratories Limited, (Nashik FDF) NDC 0378-6325-77 D-0332-2019
Class II · Moderate risk

Valsartan and Hydrochlorothiazide Tablets

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Ongoing Nitrosamine impurity Mylan Laboratories Limited, (Nashik FDF) NDC 0378-6324-77 D-0331-2019
Class II · Moderate risk

Valsartan and Hydrochlorothiazide Tablets

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Ongoing Nitrosamine impurity Mylan Laboratories Limited, (Nashik FDF) NDC 0378-6323-77 D-0330-2019
Class II · Moderate risk

Valsartan and Hydrochlorothiazide Tablets

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Ongoing Nitrosamine impurity Mylan Laboratories Limited, (Nashik FDF) NDC 0378-6322-77 D-0329-2019
Class II · Moderate risk

Valsartan and Hydrochlorothiazide Tablets

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Ongoing Nitrosamine impurity Mylan Laboratories Limited, (Nashik FDF) NDC 0378-6321-77 D-0328-2019
Class II · Moderate risk

Valsartan Tablets

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Ongoing Nitrosamine impurity Mylan Laboratories Limited, (Nashik FDF) NDC 0378-5815-77 D-0327-2019
Class II · Moderate risk

Valsartan Tablets

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Ongoing Nitrosamine impurity Mylan Laboratories Limited, (Nashik FDF) NDC 0378-5814-77 D-0326-2019
Class II · Moderate risk

Valsartan Tablets

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Ongoing Nitrosamine impurity Mylan Laboratories Limited, (Nashik FDF) NDC 0378-5813-77 D-0325-2019
Class II · Moderate risk

Valsartan Tablets

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Ongoing Nitrosamine impurity Mylan Laboratories Limited, (Nashik FDF) NDC 0378-5807-93 D-0324-2019
Class II · Moderate risk

Amlodipine and Valsartan Tablets

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Ongoing Nitrosamine impurity Mylan Laboratories Limited, (Nashik FDF) NDC 0378-1724-93 D-0323-2019
Class II · Moderate risk

Amlodipine and Valsartan Tablets

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Ongoing Nitrosamine impurity Mylan Laboratories Limited, (Nashik FDF) NDC 0378-1723-93 D-0322-2019
Class II · Moderate risk

Amlodipine and Valsartan Tablets

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Ongoing Nitrosamine impurity Mylan Laboratories Limited, (Nashik FDF) NDC 0378-1722-93 D-0321-2019
Class II · Moderate risk

Amlodipine and Valsartan Tablets

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Ongoing Nitrosamine impurity Mylan Laboratories Limited, (Nashik FDF) NDC 0378-1721-93 D-0320-2019
Class III · Low risk

Amlodipine and Olmesartan Medoxomil Tablets

Discoloration: This product is being recalled due to a confirmed pharmacist report that tablets from this lot were a pink color instead of cream (peach).

Terminated Failed specification Aurobindo Pharma USA Inc. NDC 65862-855-30 D-0289-2019
Class II · Moderate risk

Amlodipine

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Ongoing Nitrosamine impurity Teva Pharmaceuticals USA NDC 0093-7809-56 D-0310-2019
Class II · Moderate risk

Amlodipine

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Ongoing Nitrosamine impurity Teva Pharmaceuticals USA NDC 0093-7960-56 D-0309-2019
Class II · Moderate risk

Amlodipine

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Ongoing Nitrosamine impurity Teva Pharmaceuticals USA NDC 0093-7810-56 D-0308-2019
Class II · Moderate risk

Amlodipine

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Ongoing Nitrosamine impurity Teva Pharmaceuticals USA NDC 0093-7807-56 D-0307-2019